Novel purification technologies for industrial biotherapeutic manufacture

全球对更便宜的生物疗法的需求推动了降低制造成本的需求。生物疗法代表了抗击癌症等疾病的许多新工具。目前成本的很大一部分来自于目前用于确保这些治疗的安全性和有效性的净化技术。对这些技术的改进从根本上是有限的，现有的主导技术达到了无法在制造过程的其余部分实现性能提升的地步。这将影响药品制造商实现规模经济和满足患者市场需求的能力。Puridefy的新型纳米纤维净化技术有可能彻底改变生物治疗药物的工业规模生产。这种材料的性能可以通过将生产率提高10倍来克服目前的制造限制，潜在地将生物治疗制造成本降低高达25%。这将在扩大英国和世界范围内患者获得昂贵药物的渠道方面发挥重要作用。Puridefy寻求在CRD项目下开发采用的关键驱动因素。

Global demand for cheaper biotherapeutics, which represent many of the new tools in the fight against diseases such as cancer, drives the need for a reduction in manufacturing costs. A significant proportion of current costs arise from the purification technologies currently used to ensure the safety and efficacy of these treatments. Improvements to these technologies are fundamentally limited with the existing dominant technology reaching a point where it is unable to match performance increases in the rest of the manufacturing process. This will impact the ability for drug manufacturers to reach economies of scale and meet market demands from patients. Puridify’s novel nanofibre purification technology has the potential to revolutionise the industrial scale production of biotherapeutics. The material’s properties can overcome current manufacturing limitations by increasing productivity 10-fold, potentially reducing biotherapeutic manufacturing costs by up to 25%. This will play an important role in widening patient access to expensive drugs in both the UK and worldwide. Puridify seeks to develop key drivers for adoption under a CRD project.